Vascular Endothelial Growth Factor as a Potential Biomarker of Neuroinflammation and Frontal Cognitive Impairment in Patients with Alcohol Use Disorder
Requena-Ocaña, Nerea (Universidad Complutense de Madrid. Departamento de Psicobiología)
Flores-López, María (Hospital Regional Universitario de Málaga)
Papaseit, Esther (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
García-Marchena, Nuria (Institut Germans Trias i Pujol)
Ruiz, Juan Jesús (Centro Provincial de Drogodependencias (CPD) de Málaga)
Ortega-Pinazo, Jesús (Hospital Regional Universitario de Málaga)
Serrano, Antonia (Hospital Regional Universitario de Málaga)
Pavón-Morón, Francisco Javier (Centro de Investigación Biomédica en Red en Enfermedades Cardiovasculares)
Farre, Magi (Universitat Autònoma de Barcelona. Departament de Farmacologia, de Terapèutica i de Toxicologia)
Suarez, Juan (Department of Anatomy, Legal Medicine and History of Science, School of Medicine, University of Malaga)
Rodríguez de Fonseca, Fernando (Hospital Regional Universitario de Málaga)
Araos, Pedro (Universidad de Málaga. Departamento de Psicobiología y Metodología de las Ciencias del Comportamiento)

Data:	2022
Resum:	(1) Background: Alcohol Use Disorder (AUD) is associated with functional disruption of several brain structures that may trigger cognitive dysfunction. One of the mechanisms of alcohol-associated cognitive impairment has been proposed to arise from its direct impact on the immune system, which culminates in the release of cytokines and chemokines which can eventually reach the brain. Alcohol can also disrupt the blood-brain barrier, facilitating the penetration of pro-inflammatory molecules throughout vascular endothelial growth factor A (VEGFA). Thus, alcohol-induced alterations in chemokines and VEGFA might contribute to the neuroinflammation and cognitive impairment associated with AUD. (2) Methods: The present cross-sectional study investigates whether patients with AUD (n = 86) present cognitive disability associated to alterations in plasma concentration of SDF-1, fractalkine, eotaxin, MCP-1, MIP-1α and VEGFA when compared to control subjects (n = 51). (3) Results: The analysis indicated that SDF-1 and MCP-1 concentrations were higher in AUD patients than in controls. Concentrations of VEGFA were higher in AUD patients with severe frontal deficits, and the score of frontal lobe functions was negatively correlated with VEGFA and fractalkine. Acute alcohol effects on VEGFA plasma levels in healthy volunteers demonstrated the induction of VEGFA release by heavy alcohol drinking. VEGFA was positively correlated with pro-inflammatory chemokines in AUD patients with frontal cognitive impairment. (4) Conclusions: we propose VEGFA/chemokine monitoring as biomarkers of potential cognitive impairment in AUD patients.
Ajuts:	Ministerio de Economía y Competitividad RD16/0017/0001 Instituto de Salud Carlos III RD16/0017/003 Instituto de Salud Carlos III PI20/01399 Instituto de Salud Carlos III PI19/01577 Instituto de Salud Carlos III PI19/00886 Instituto de Salud Carlos III CD19/00019 Instituto de Salud Carlos III FI18/00249
Drets:	Aquest document està subjecte a una llicència d'ús Creative Commons. Es permet la reproducció total o parcial, la distribució, la comunicació pública de l'obra i la creació d'obres derivades, fins i tot amb finalitats comercials, sempre i quan es reconegui l'autoria de l'obra original.
Llengua:	Anglès
Document:	Article ; recerca ; Versió publicada
Matèria:	Alcohol use disorders ; Addiction ; VEGFA ; Blood-brain barrier ; Chemokines ; Fractalkine ; Neuroinflammation ; Cognitive dysfunction ; Neurodegeneration ; Dementia
Publicat a:	Biomedicines, Vol. 10 (april 2022) , ISSN 2227-9059

DOI: 10.3390/biomedicines10050947
PMID: 35625687

19 p, 2.3 MB

El registre apareix a les col·leccions:
Articles > Articles de recerca
Articles > Articles publicats